Wahlich Charlotte, Chandrasekaran Lakshmi, Chaudhry Umar A R, Willis Kathryn, Chambers Ryan, Bolter Louis, Anderson John, Shakespeare Royce, Olvera-Barrios Abraham, Fajtl Jiri, Welikala Roshan, Barman Sarah, Egan Catherine A, Tufail Adnan, Owen Christopher G, Rudnicka Alicja R
Population Health Research Institute, St George's School of Health and Medical Sciences, City St George's, University of London, London, UK.
Population Health Research Institute, St George's School of Health and Medical Sciences, City St George's, University of London, London, UK.
Diabetes Res Clin Pract. 2025 Jan;219:111964. doi: 10.1016/j.diabres.2024.111964. Epub 2024 Dec 19.
Automated retinal image analysis using Artificial Intelligence (AI) can detect diabetic retinopathy as accurately as human graders, but it is not yet licensed in the NHS Diabetic Eye Screening Programme (DESP) in England. This study aims to assess perceptions of People Living with Diabetes (PLD) and Healthcare Practitioners (HCP) towards AI's introduction in DESP.
Two online surveys were co-developed with PLD and HCP from a diverse DESP in North East London. Surveys were validated through interviews across three centres and distributed via DESP centres, charities, and the British Association of Retinal Screeners. A coding framework was used to analyse free-text responses.
387 (24%) PLD and 98 (37%) HCP provided comments. Themes included trust, workforce impact, the patient-practitioner relationship, AI implementation challenges, and inequalities. Both groups agreed AI in DESP was inevitable, would improve efficiency, and save costs. Concerns included job losses, data security, and AI decision safety. A common misconception was that AI would directly affect patient interactions, though it only processes retinal images.
Limited understanding of AI was a barrier to acceptance. Educating diverse PLD groups and HCP about AI's accuracy and reliability is crucial to building trust and facilitating its integration into screening practices.
使用人工智能(AI)进行自动视网膜图像分析检测糖尿病视网膜病变的准确性可与人类分级员相媲美,但在英国国民健康服务体系糖尿病眼部筛查计划(DESP)中尚未获得许可。本研究旨在评估糖尿病患者(PLD)和医疗从业者(HCP)对在DESP中引入AI的看法。
与来自伦敦东北部不同DESP的PLD和HCP共同开发了两项在线调查。通过在三个中心进行访谈对调查进行了验证,并通过DESP中心、慈善机构和英国视网膜筛查协会进行分发。使用编码框架分析自由文本回复。
387名(24%)PLD和98名(37%)HCP提供了评论。主题包括信任、劳动力影响、医患关系、AI实施挑战和不平等。两组都认为DESP中引入AI是不可避免的,将提高效率并节省成本。担忧包括失业、数据安全和AI决策安全性。一个常见的误解是AI会直接影响患者互动,而实际上它只处理视网膜图像。
对AI的有限理解是接受的障碍。对不同的PLD群体和HCP进行关于AI准确性和可靠性的教育对于建立信任并促进其融入筛查实践至关重要。